HROW

Business Context and Reporting Period

Company: Transdel Pharmaceuticals, Inc. (Note: Metadata listed "Harrow, Inc." but filing text confirms Transdel Pharmaceuticals, Inc.)
Period: Quarterly Report (Form 10-Q) for the period ended September 30, 2008.
Business Model: A development-stage specialty pharmaceutical company focused on non-invasive topically delivered products. The lead candidate is Ketotransdel™, a topical NSAID for pain management. The company has generated no revenue since inception (July 24, 1998) and relies on financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Increased significantly for the nine months ended September 30, 2008 ($2.78M) compared to the same period in 2007 ($1.31M). This was driven by higher Selling, General, and Administrative (SG&A) expenses ($1.32M vs. $0.50M) and increased Research and Development (R&D) costs ($1.47M vs. $0.81M).
• Net Loss: The net loss for the nine months ended September 30, 2008, was $2.35M, an improvement from the $2.76M loss in the prior year period. This improvement was largely due to a $375,000 gain on a legal settlement and $56,049 in interest income, offsetting higher operating costs.
• Liquidity: Cash and cash equivalents increased from $3.71M at December 31, 2007, to $5.78M at September 30, 2008, primarily due to net proceeds of $3.94M from private placements of common stock.
• Debt: The company had no outstanding notes payable as of September 30, 2008, following the conversion of $1.5M in 2007 notes into common stock in the prior year.

Guidance, Outlook, and Risks

• Going Concern: Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern. The company has incurred recurring losses and negative operating cash flows since inception. Continuation depends on obtaining additional financing.
• Clinical Progress: The company initiated its Phase 3 clinical program for Ketotransdel™ in June 2008, with the first patient enrolled in September 2008. Top-line results are anticipated in the second half of 2009. A second Phase 3 study for osteoarthritis is being assessed.
• Financing Needs: The company explicitly states it will need to raise additional funds to execute its operating plan over the next twelve months. There is no assurance that financing will be available on acceptable terms.
• Key Risks:
  • Failure to obtain FDA approval for Ketotransdel™.
  • Inability to secure additional capital, potentially forcing a delay or termination of clinical trials.
  • Dependence on third-party manufacturers and contract research organizations (Cato Research Ltd. agreement estimated at $3.3M).
  • Stock-based compensation and dilution from future equity offerings.

Investor Verification Checklist

• Cash Runway: Verify if the $5.78M cash balance is sufficient to fund the Phase 3 trial (estimated $3.3M with Cato) and general operations through 2009 without further dilution.
• Private Placement Terms: Review the terms of the May 2008 and September 2007 private placements, including warrant exercise prices ($4.40/$5.50 and $4.00/$5.00) and potential dilution.
• Legal Settlement: Confirm the finality of the $375,000 net gain from the law firm mediation settlement and ensure no further liabilities exist.
• Consulting Agreements: Scrutinize the prepaid consulting fees ($764) and the subsequent issuance of shares to investor relations firms (82,568 shares issued Oct 2008) for potential future expense recognition.
• Stock Option Liability: Note the $791,000 in unrecognized stock-based compensation expense expected to be recognized over 2.3 years.